Previous close | 38.92 |
Open | 38.95 |
Bid | 38.65 x 48300 |
Ask | 38.67 x 51100 |
Day's range | 38.58 - 39.10 |
52-week range | 33.75 - 44.81 |
Volume | |
Avg. volume | 643,880 |
Market cap | 8.627B |
Beta (5Y monthly) | 0.42 |
PE ratio (TTM) | 26.98 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.18 (2.94%) |
Ex-dividend date | 30 Jan 2024 |
1y target est | N/A |
Evaluate the expected performance of Qiagen (QGEN) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
QIAGEN's (QGEN) new products, coupled with the IVD version of QIAGEN's digital PCR platform QIAcuity, are planned to be released in mid-2024.
With QIAGEN's (QGEN) QIAstat-Dx Analyzer 2.0's integration of remote access, central and regional laboratories may work together efficiently, particularly when it comes to decentralized testing.